Standard BioTools Inc.
LAB Healthcare Medical Devices
In the quarter to June 2026, revenue fell 7.62%, EPS grew 22.2%, free cash flow grew 52.8% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow LAB
Standard BioTools Inc. (LAB) EV/Sales
As of 16 October 2026, Standard BioTools Inc. (LAB) trades at a EV/Sales of −2.7×. Over the past ten years it has ranged from −2.7× (October 2026) to 11.5× (March 2015) — the current reading is the lowest in ten years. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.6× | (1.22%) |
| FY2024 | 3.6× | 453.26% |
| FY2023 | 0.7× | 7,036.96% |
| FY2022 | 0.0× | (99.65%) |
| FY2021 | 2.6× | (14.63%) |
| FY2020 | 3.0× | 55.73% |
| FY2019 | 2.0× | (47.18%) |
| FY2018 | 3.7× | 11.86% |
| FY2017 | 3.3× | (2.76%) |
| FY2016 | 3.4× | (4.74%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −1.8× | — |
| Mar 2026 | −1.1× | — |
| Dec 2025 | 3.6× | (27.23%) |
| Sep 2025 | 4.9× | 42.48% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LAB Standard BioTools Inc. | −2.7× |
| TMCI Treace Medical Concepts, Inc. compare | 1.3× |
| INFU InfuSystems Holdings, Inc. compare | 2.0× |
| ELMD Electromed, Inc. compare | 2.8× |
| TLSI TriSalus Life Sciences, Inc. compare | 4.4× |
| CLPT ClearPoint Neuro, Inc. compare | 7.0× |
| PROF Profound Medical compare | 9.9× |
| CATX Perspective Therapeutics, Inc. compare | 64.7× |
| QSI Quantum-Si Incorporated compare | 82.4× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)